ScreenerHero

ELOX Eloxx Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · eloxxpharma.com
14.88USD-1.65%Mkt Cap: 60.06M $P/E: 4.23

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap60.06M USD
Enterprise Value10.94M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.00M USD
Revenue/Share—
Last Price14.88 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)4.23
P/E (Forward)-21.31
PEG1.85
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.32
EPS (TTM)3.41
EPS (Forward)-0.71
52W Range
0.000064% of range23.40
52W High23.40 USD
52W Low0.0000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE50.35%
ROA-113.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.33M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-50.13M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.08
Current Ratio3.74
Quick Ratio3.65
Book Value/Sh11.50 USD
Cash/Share15.35 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 20, 2017
Analyst Consensus
Rating—
Target (Mean)38.25 USD
Upside (mean)+157.1%
Target Range32.00 USD – 43.00 USD
32.00+157.1% to mean43.00
# Analysts4
Ownership
Shares Out.4.04M
Float931.13K
Insiders19.06%
Institutions73.76%
Short Interest
Short Ratio1.0d
Short % Float1.25%
Short % Out.1.13%
Shares Short45.63K
Short (prev mo.)24.45K
Technical
SMA 5016.69 (-10.8%)
SMA 20014.98 (-0.7%)
Beta-171332.88
S&P 52W Chg16.45%
Avg Vol (30d)36.09K
Avg Vol (10d)18.41K
Technical Indicators
RSI (14)44.0
MACD-0.2826
MACD Signal-0.1310
MACD Hist.-0.1515
BB Upper17.78 USD
BB Middle15.98 USD
BB Lower14.17 USD
BB Width22.57%
ATR (14)1.593 USD
Vol Ratio (20d)0.56x